Effect of Inhaled Tiotropium on Spirometric Parameters in Patients with Tuberculous Destroyed Lung

Abstract

BackgroundIn Korea, patients with destroyed lung due to tuberculosis (TB) account for a significant portion of those affected by chronic pulmonary function impairment. The objective of our research was to evaluate the efficacy of inhaled tiotropium bromide in TB destroyed lung.MethodsWe compared the effectiveness of inhaled tiotropium bromide for 2 months between pre- and post-treatment pulmonary function tests performed on 29 patients with destroyed lung due to TB.ResultsThe mean age of the total number of patients was 63±9 years, where 15 patients were male. The pre-treatment mean forced expiratory volume in 1 second (FEV1) was 1.02±0.31 L (44.1±16.0% predicted). The pre-treatment mean forced vital capacity (FVC) was 1.70±0.54 L (52.2±15.8% predicted). Overall, the change in FEV1% predicted over baseline with tiotropium was 19.5±19.1% (p<0.001). Twenty patients (72%) got better than a 10% increase in FEV1 over baseline with tiotropium, but one patient showed more than a 10% decrease in FEV1. Overall, the change in FVC% predicted over baseline with tiotropium was 18.5±19.9% (p<0.001). Seventeen patients (59%) experienced greater than a 10% increase in FVC over baseline with tiotropium; 12 (41%) patients had stable lung function.ConclusionThe inhaled tiotropium bromide therapy may lead to improve lung functions in patients with TB destroyed lung. However, the long-term effectiveness of this treatment still needs to be further assessed.

Tiotropium Is Predicted to Be a Promising Drug for COVID-19 Through Transcriptome-Based Comprehensive Molecular Pathway Analysis

“…On the other hand, another potent drug rapamycin, which is an immunosuppressant inhibiting the mammalian target of rapamycin (mTOR) pathway, showed some unfavored effects such as augmenting LPS-induced lung injury [ 43 , 44 ], while it also reduced inflammation by inhibiting the NFκB-signaling pathway through the mTOR pathway. Lastly, as a clinically proven drug for chronic obstructive pulmonary disease (COPD) [ 16 ] and asthma [ 45 ], there are several lines of evidence showing that tiotropium improved lung functions [ 46 ]. Therefore, we recommend that it is worthwhile to test whether tiotropium can alleviate the symptoms of COVID-19 and prevent disease progression.…”

Tuberculosis associated chronic obstructive pulmonary disease

“…Treatment of TOPD is no difference than treatment of COPD alone. Yum et al studied the efficacy of inhaled tiotropium bromide for 2 months period on 29 patients with tuberculous destroyed lungs. There was a significant improvement in FEV 1 and FVC value over baseline with tiotropium therapy.…”

Effect of Tiotropium on Post Pulmonary TB Patients With Obstructive Abnormalities to Lung Function and Quality of Life

“…[13][14][15] Penggunaan tiotropium sebagai bronkodilator dan terapi obstruksi pada pasien bekas TB, diteliti oleh Yum HK, dkk di Korea dengan hasil terdapat peningkatan fungsi paru pada 59% pasien. 16,17 Penilaian dan evaluasi kualitas hidup pasien dengan kelainan obstruksi merupakan hal yang penting untuk mempertahankan terapi dan meningkatkan kualitas hidup pasien sehari-hari. 18,19 Kuisioner St George Respiratory Quessionnare (SGRQ) merupakan instrumen yang paling sering digunakan untuk menilai kualitas hidup pasien dengan kelainan paru.…”